The New Ordinary Shares will have the same rights as the Existing Ordinary Shares including with respect to
voting, dividends, returns of capital and other rights.
The Deferred Shares will have no dividend or voting rights and, upon a return of capital, the
right only to receive the amount paid up thereon after the holders of the New Ordinary Shares in the capital of the Company have received the amounts entitlted to be paid to holders of New Ordinary Shares in the share capital of the Company and the
further payment of £10,000,000 in respect of each New Ordinary Share. Deferred shares are commonly used by U.K. public companies to restructure the nominal value of their ordinary share capital. Once created for this reason, it is not uncommon
for deferred shares to be cancelled using one of the procedures available to the Company under U.K. company law and the Board will in due course consider whether cancellation is necessary or desirable and update shareholders accordingly.
No share certificates will be issued in respect of the Deferred Shares and the CREST accounts of holders of New Ordinary Shares will not be credited with any
Deferred Shares.
A copy of the Companys Current Articles and the proposed New Articles will be available for inspection during normal business
hours (excluding Saturdays, Sundays and bank holidays) at 3 Lochside Way, Edinburgh EH12 9DT from the date of this Notice until the close of the General Meeting. The proposed New Articles will also be available for inspection at the General Meeting
at least 30 minutes prior to the start of the meeting and up until the close of the meeting.
THE BOARD RECOMMENDS YOU VOTE FOR THE CAPITAL
REORGANISATION (RESOLUTION 1) AND FOR THE ADOPTION OF THE NEW ARTICLES (SPECIAL RESOLUTION 3).
Background to Ordinary Resolution 2 and Special
Resolution 4
As a matter of U.K. company law, directors of a company incorporated in England must have authority from shareholders to allot or grant
rights to subscribe for, or to convert any security into, the companys shares. In addition, when an allotment of shares is for cash, the company must first offer those shares on the same terms to existing shareholders of the company on a pro-rata basis (commonly referred to as statutory pre-emption rights) unless these statutory pre-emption rights are dis-applied, by approval of the shareholders.
Resolutions 2 and 4, which we refer to as our Share Issuance
Proposals, ask our shareholders for authority for the directors to allot shares or grant rights over shares up to an aggregate nominal amount of £20,000,000 and the power for the directors to allot shares or grant rights over shares for
cash up to an aggregate nominal amount of £20,000,000 on a non-preemptive basis.
These Resolutions, if
passed, extend (and replace) the power and authorities given at the 2024 AGM, which would otherwise have lapsed at the conclusion of the 2025 AGM. Given that we will be holding our 2025 AGM in June 2025, we feel it is sensible for the authorities
contained within the Share Issuance Proposals to last for a slightly extended period, commencing now and lasting until 30 June 2026 or, if earlier, the conclusion of our 2026 AGM, rather than expiring and having to be re-taken at the imminent 2025 AGM.
Many of our peer companies are incorporated in the United States, and are thus not
subject to similar share issuance restrictions. We are asking you to approve our Share Issuance Proposals to allow us to continue to execute on our business and growth strategy in a timely and competitive manner.
Should our shareholders not approve Resolutions 2 and 4, whilst we appreciate that we would still have the ability to seek shareholder approval in connection
with a specific issuance of shares on a case-by-case basis by convening general meetings from time to time, we do not believe that such an approach is a workable
alternative to obtaining approval of Resolutions 2 and 4 at the General Meeting as we propose. The uncertainty as to whether we could obtain shareholder approval for a specific issuance, as well as the delays we would experience in seeking and
obtaining such approval, could be harmful to the terms of such a share issuance. In addition, the case-by-case approval approach ignores market windows and other deal
timing and competitive realities.
Specifically, the requirement to first offer shares, that we propose to issue for cash, to all of our existing
shareholders by way of time-consuming pro-rata rights offerings would considerably reduce the speed at which we could complete capital-raising activities undertaken in furtherance of our growth strategy. It
would also increase our costs, might otherwise make it difficult or impossible for us to complete such transactions, and could put us at a distinct competitive disadvantage relative to our peer companies.
Access to capital and the ability to raise equity capital at short notice have been important factors that have contributed to our ability to execute our
long-term growth strategy. In practice, offering shares to existing shareholders in accordance with U.K. statutory pre-emption rights can be time-consuming, so U.K. market practice for listed companies is to
annually seek a shareholder resolution waiving or dis-applying pre-emption rights over new share issuances for cash, up to an agreed limit.
We fully appreciate that our proposals are in excess of the investment advisory guidance in this regard and for this reason, our proposals may attract a
negative voting recommendation from certain proxy advisory firms. However, we have an established track record since our IPO in October 2017 of securing annual shareholder support for a resolution dis-applying
pre-emption rights over amounts of share capital in excess of the investment advisory guidance. Using these authorities, we have responsibly raised capital in order to execute our business plan.
6